MDMX: from bench to bedside

Cited by (234)

Items 101–200 of 234

1. Targeting Mdmx to treat breast cancers with wild-type p53
   Sue Haupt, D Buckley, J-MB Pang, J Panimaya, Piotr Jan Paul, Cristina Gamell, Elena A. Takano, Y Ying Lee, Sanne Hiddingh, T-M Rogers et al. · 2015 · Cell Death and Disease
2. Structural and Functional Comparison of the RING Domains of Two p53 E3 Ligases, Mdm2 and Pirh2
   Shloush, Jonathan, Vlassov, John E., Engson, Ian, Duan, Shili, Saridakis, Vivian, Dhe-paganon, Sirano, Raught, Brian, Sheng, Yi, Arrowsmith, Cheryl H. · 2011 · Journal of Biological Chemistry
3. Design of ultrahigh-affinity and dual-specificity peptide antagonists of MDM2 and MDMX for P53 activation and tumor suppression
   Xiang Li, Neelakshi Gohain, Si Chen, Yinghua Li, Xiaoyuan Zhao, Bo Li, William David Tolbert, Wangxiao He, Marzena Pazgier, Honggang Hu et al. · 2021 · Acta Pharmaceutica Sinica B
4. Estrogen receptor alpha (ERα/ESR1) mediates the p53-independent overexpression of MDM4/MDMX and MDM2 in human breast cancer
   Wendy M. Swetzig, Jianmin Wang, Gokul M. Das · 2016 · Oncotarget
5. Maternal Embryonic Leucine Zipper Kinase (MELK) Reduces Replication Stress in Glioblastoma Cells
   Cenk Kığ, Monique Beullens, Lijs Beke, Aleyde Van Eynde, Johannes T. Linders, Dirk Brehmer, Mathieu Bollen · 2013 · Journal of Biological Chemistry · Retracted
6. The Role of MDM2 in Promoting Genome Stability versus Instability
   Mohammad Reza Saadatzadeh, Adily N. Elmi, Pankita H. Pandya, Khadijeh Bijangi‐Vishehsaraei, Jixin Ding, Christopher W. Stamatkin, Aaron Cohen‐Gadol, Karen E. Pollok · 2017 · International Journal of Molecular Sciences
7. Gene Activation by Dissociation of an Inhibitor from a Transcriptional Activation Domain
   Feng‐Lei Jiang, Benjamin R. Frey, Margery L. Evans, Jordan C. Friel, James E. Hopper · 2009 · Molecular and Cellular Biology
8. MDM2/X inhibitors as radiosensitizers for glioblastoma targeted therapy
   Miles, Xanthene, Vandevoorde, Charlot, Hunter, Alistair, Bolcaen, Julie · 2021 · Frontiers in Oncology
9. Potential therapeutic targets ofTP53gene in the context of its classically canonical functions and its latest non-canonical functions in human cancer
   Toshimichi Tanaka, Masahiko Watanabe, Keishi Yamashita · 2018 · Oncotarget
10. MDM2 and MDMX in Cancer and Development
    Jean‐Christophe Marine · 2011 · Current topics in developmental biology/Current Topics in Developmental Biology
11. Thyroid tumorigenesis and molecular markers in thyroid cancer
    Guennadi Kouniavsky, Martha A. Zeiger · 2009 · Current Opinion in Oncology
12. Switching on p53: an essential role for protein phosphorylation?
    Jayne Loughery, David W. Meek · 2013 · Biodiscovery
13. Designer macrocyclic organo-peptide hybrids inhibit the interaction between p53 and HDM2/X by accommodating a functional α-helix
    Jessica M. Smith, John R. Frost, Rudi Fasan · 2014 · Chemical Communications
14. Functional consequences of retro-inverso isomerization of a miniature protein inhibitor of the p53–MDM2 interaction
    Chong Li, Changyou Zhan, Le Zhao, Xishan Chen, Weiyue Lu, Wuyuan Lu · 2013 · Bioorganic & Medicinal Chemistry
15. Expression of p14, MDM2, and MDM4 in human retinoblastoma
    Ying Guo, Sanja Pajovic, Brenda L. Gallie · 2008 · Biochemical and Biophysical Research Communications
16. Ligand Binding Mode Prediction by Docking: Mdm2/Mdmx Inhibitors as a Case Study
    Nagakumar Bharatham, Kavitha Bharatham, Anang A. Shelat, Donald Bashford · 2013 · Journal of Chemical Information and Modeling
17. Pro- and anti-apoptotic effects of p53 in cisplatin-treated human testicular cancer are cell context-dependent
    Alessandra di Pietro, Roelof Koster, Wytske Boersma‐van Ek, Wendy Dam, Nanno H. Mulder, Jourik A. Gietema, Elisabeth G.E. de Vries, Steven de Jong · 2012 · Cell Cycle
18. Tight regulation of p53 activity by Mdm2 is required for ureteric bud growth and branching
    Sylvia A. Hilliard, Karam Aboudehen, Xiao Yao, Samir Sayem El-Dahr · 2011 · Developmental Biology
19. Widespread Overexpression of Epitope-Tagged Mdm4 Does Not Accelerate Tumor Formation In Vivo
    De Clercq, Sarah, Gembarska, Agnieszka, Denecker, Geertrui, Maetens, Marion, Naessens, Michael, Haigh, Katharina, Haigh, Jody J., Marine, Jean-Christophe · 2010 · Molecular and Cellular Biology
20. Verbenalin attenuates hepatic damage and mitochondrial dysfunction in alcohol-associated steatohepatitis by regulating MDMX/PPARα-mediated ferroptosis
    Jiahui Dong, Changlin Du, Chuanting Xu, Qi Wang, Zhonghao Wang, Fanle Zeng, Zhenzhen Qian, Lei Zhang, Xiongwen Lv, Zhang Lei et al. · 2023 · Journal of Ethnopharmacology
21. The p53-Mdm2 Loop: A Critical Juncture of Stress Response
    Yaara Levav-Cohen, Zehavit Goldberg, Kah Hin Tan, Osnat Alsheich-Bartok, Valentina Zuckerman, Sue Haupt, Ygal Haupt · 2014 · Sub-cellular biochemistry/Subcellular biochemistry
22. CDK9 activity is critical for maintaining MDM4 overexpression in tumor cells
    Monika Štětková, Kateřina Growková, Petr Fojtík, Barbora Valčíková, Veronika Palušová, Amandine Verlande, Radek Jorda, Vladimı́r Kryštof, Václav Hejret, Panagiotis Alexiou et al. · 2020 · Cell Death and Disease
23. Cytoplasmic tethering is involved in synergistic inhibition of p53 by Mdmx and Mdm2
    Ohtsubo, Chihiro, Shiokawa, Daisuke, Kodama, Masami, Gaiddon, Christian, Nakagama, Hitoshi, Jochemsen, Aart G., Taya, Yoichi, Okamoto, Koji · 2009 · Cancer Science
24. Influence of MDM2 and MDM4 on development and survival in hereditary retinoblastoma
    Adriana Helena de Oliveira Reis, Ivna Néria Silva Ribamar de Carvalho, Paula Batista de Sousa Damasceno, Sima Ferman, Evandro Lucena, Jorge S. López‐Camelo, Hector Nicolas Seuánez, Fernando Regla Vargas · 2011 · Pediatric Blood & Cancer
25. Inhibitors of MDM2 and MDMX: A Structural Perspective
    Christiane Riedinger, James M. McDonnell · 2009 · Future Medicinal Chemistry
26. The p53 inhibitor Mdm4 cooperates with multiple genetic lesions in tumourigenesis
    Shunbin Xiong, Vinod Pant, Yun Zhang, Neeraj K. Aryal, Mingjian James You, Donna F. Kusewitt, Guillermina Lozano · 2016 · The Journal of Pathology
27. Mutated p53 in HGSC—From a Common Mutation to a Target for Therapy
    Aya Saleh, Ruth Perets · 2021 · Cancers
28. Mathematical modelling of p53 basal dynamics and DNA damage response
    Ket Hing Chong, Sandhya Samarasinghe, Don Kulasiri · 2014 · Mathematical Biosciences
29. Puzzling over MDM4–p53 network
    F. Mancini, Giusy Di Conza, Olimpia Monti, Antonio Macchiarulo, Roberto Pellicciari, Alfredo Pontecorvi, Fabiola Moretti · 2010 · The International Journal of Biochemistry & Cell Biology
30. Stochastic and Deterministic Models of Cellular p53 Regulation
    Gerald B. Leenders, Jack A. Tuszyński · 2013 · Frontiers in Oncology
31. Inhibition of Retinoblastoma In Vitro and In Vivo with Conditionally Replicating Oncolytic Adenovirus H101
    Xin Song, Yixiong Zhou, Renbing Jia, Xiaofang Xu, Haibo Wang, Ji‐Fan Hu, Shengfang Ge, Xianqun Fan · 2010 · Investigative Ophthalmology & Visual Science
32. Competitive Binding between Dynamic p53 Transactivation Subdomains to Human MDM2 Protein
    Bing Shan, Dawei Li, Lei Bruschweiler‐Li, Rafael Brüschweiler · 2012 · Journal of Biological Chemistry
33. Diaryl- and triaryl-pyrrole derivatives: inhibitors of the MDM2–p53 and MDMX–p53 protein–protein interactions
    Tim J. Blackburn, Shafiq Uddin Ahmed, Christopher R. Coxon, Junfeng Liu, Xiaohong Lü, Bernard T. Golding, Roger J. Griffin, Claire Hutton, David R. Newell, O. Stephen Ojo et al. · 2013 · MedChemComm
34. TP 53 pathway analysis in paediatric Burkitt lymphoma reveals increased MDM 4 expression as the only TP 53 pathway abnormality detected in a subset of cases
    Leventaki, Vasiliki, Rodic, Vladimir, Tripp, Sheryl R., Bayerl, Michael G., Perkins, Sherrie L., Barnette, Phillip, Schiffman, Joshua D., Miles, Rodney R. · 2012 · British Journal of Haematology
35. Calculation of hot spots for protein–protein interaction in p53/PMI‐MDM2/MDMX complexes
    Dading Huang, Yifei Qi, Jianing Song, John Z. H. Zhang · 2018 · Journal of Computational Chemistry
36. Computational Studies of Difference in Binding Modes of Peptide and Non-Peptide Inhibitors to MDM2/MDMX Based on Molecular Dynamics Simulations
    Jianzhong Chen, Dinglin Zhang, Yuxin Zhang, Guohui Li · 2012 · International Journal of Molecular Sciences
37. Functional analysis and consequences of Mdm2 E3 ligase inhibition in human tumor cells
    Mark R. Wade, Y C Li, A S Matani, Simon M. G. Braun, Francesca Milanesi, Luo Wei Rodewald, Geoffrey M. Wahl · 2012 · Oncogene
38. Affinity-based screening of MDM2/MDMX–p53 interaction inhibitors by chemical array: Identification of novel peptidic inhibitors
    Noguchi, Taro, Oishi, Shinya, Honda, Kaori, Kondoh, Yasumitsu, Saito, Tamio, Kubo, Tatsuhiko, Kaneda, Masato, Ohno, Hiroaki, Osada, Hiroyuki, Fujii, Nobutaka · 2013 · Bioorganic & Medicinal Chemistry Letters
39. Protein phosphatase 1 inhibits p53 signaling by dephosphorylating and stabilizing Mdmx
    Zengxin Lu, Guohui Wan, Huarong Guo, Xinna Zhang, Xiongbin Lu · 2012 · Cellular Signalling
40. Peli1 Modulates the Subcellular Localization and Activity of Mdmx
    Dawei Li, Omid Tavana, Shao‐Cong Sun, Wei Gu · 2018 · Cancer Research
41. The roles of mouse double minute 2 (MDM2) oncoprotein in ocular diseases: A review
    Heng Jiang, Jing Luo, Hetian Lei · 2022 · Experimental Eye Research
42. Peptide Activators of the p53 Tumor Suppressor
    Changyou Zhan, Wuyuan Lu · 2011 · Current Pharmaceutical Design
43. N-Acylpolyamine inhibitors of HDM2 and HDMX binding to p53
    Ryo Hayashi, Deyun Wang, Toshiaki J. Hara, Jaclyn A. Iera, Stewart R. Durell, Daniel H. Appella · 2009 · Bioorganic & Medicinal Chemistry
44. Modulation of alternative splicing by anticancer drugs
    Sayeed Ur Rehman, Mohammed Amir Husain, Tarique Sarwar, Hassan Mubarak Ishqi, Mohammad Tabish · 2015 · Wiley Interdisciplinary Reviews - RNA
45. Targeting Oncogenic Protein-Protein Interactions by Diversity Oriented Synthesis and Combinatorial Chemistry Approaches
    Andreas G. Tzakos, Demosthenes Fokas, Charlie Johannes, Vassilios Moussis, Eleftheria ChR. Hatzimichael, Evangelos C. Briasoulis · 2011 · Molecules
46. Molecular modeling and molecular dynamics simulation studies on pyrrolopyrimidine-based α-helix mimetic as dual inhibitors of MDM2 and MDMX
    Shaoyong Lu, Yong‐Jun Jiang, Jian‐Wei Zou, Tianxing Wu · 2011 · Journal of Molecular Graphics and Modelling
47. Absolute Binding Free Energy Calculations for Highly Flexible Protein MDM2 and Its Inhibitors
    Nidhi Singh, Wenjin Li · 2020 · International Journal of Molecular Sciences
48. Protecting the genome from mdm2 and mdmx
    Melo, A. N., Eischen, C. M. · 2012 · Genes & Cancer
49. Employing artificial neural networks and fluorescence spectrum for food vegetable oils identification
    Wawan Joko Pranoto, Sarmad Ghazi Al‐Shawi, Paitoon Chetthamrongchai, Tzu-Chia Chen, Ekaterina Pavlovna Petukhova, Natalia Nikolaeva, Walid Kamal Abdelbasset, N Yushchenko, Aravindhan Surendar · 2021 · Food Science and Technology
50. Fragment-Based Library Generation for the Discovery of a Peptidomimetic p53-Mdm4 Inhibitor
    André Boltjes, Yijun Huang, Rob van de Velde, Laurie K. Rijkee, Siglinde Wolf, James A. Gaugler, Katarzyna Leśniak, Katarzyna Guzik, Tad A. Holak, Alexander S. S. Dömling · 2014 · ACS Combinatorial Science
51. S‐MDM4 mRNA overexpression indicates a poor prognosis and marks a potential therapeutic target in chronic lymphocytic leukemia
    Ling Liu, Lei Fan, Fang Cheng, Zhi‐Jian Zou, Shu Yang, Lina Zhang, Jianyong Li, Wei Xu · 2012 · Cancer Science
52. Interactions between MDM2 and TP53 Genetic Alterations, and Their Impact on Response to MDM2 Inhibitors and Other Chemotherapeutic Drugs in Cancer Cells
    Wanqing Liu, Lijun He, Jacqueline Ramı́rez, Mark J. Ratain · 2009 · Clinical Cancer Research
53. Strategy and Tactics for Designing Analogs: Biochemical Characterization of the Large Molecules
    Jung‐Mo Ahn, Kara Kassees, T-K. Lee, Bikash Manandhar, Ali Munaim Yousif · 2016 · Elsevier eBooks
54. Low‐dose mithramycin exerts its anticancer effect via the p53 signaling pathway and synergizes with nutlin‐3 in gynecologic cancers
    Tatsuhiro Ohgami, Kiyoko Kato, Hiroaki Kobayashi, Kenzo Sonoda, Takafumi Inoue, Shinichiro Yamaguchi, Tomoko Yoneda, Norio Wake · 2010 · Cancer Science
55. Expanding the horizon of chemotherapeutic targets: From MDM2 to MDMX (MDM4)
    Antonio Macchiarulo, Nicola Giacchè, Andrea Carotti, Fabiola Moretti, Roberto Pellicciari · 2011 · MedChemComm
56. Deconstructing nucleotide binding activity of the Mdm2 RING domain
    Christina Priest, Carol L. Prives, Masha V. Poyurovsky · 2010 · Nucleic Acids Research
57. p53–MDM2 and MDMX Antagonists
    Constantinos G. Neochoritis, Natalia Estrada‐Ortiz, Kareem Khoury, Alexander S. S. Dömling · 2014 · Annual reports in medicinal chemistry
58. Apamin as a Template for Structure‐Based Rational Design of Potent Peptide Activators of p53
    Chong Li, Marzena Pazgier, Min Liu, Wei‐Yue Lu, Wuyuan Lu · 2009 · Angewandte Chemie
59. Oncogenic functions of hMDMX in in vitro transformation of primary human fibroblasts and embryonic retinoblasts
    Lenos, Kristiaan, de Lange, Job, Teunisse, Amina FAS, Lodder, Kirsten, Verlaan-de Vries, Matty, Wiercinska, Eliza, van der Burg, Marja JM, Szuhai, Karoly, Jochemsen, Aart G · 2011 · Molecular Cancer
60. Self-Association of the Gal4 Inhibitor Protein Gal80 Is Impaired by Gal3: Evidence for a New Mechanism in the GAL Gene Switch
    Onur Egriboz, Sudip Goswami, Xiaorong Tao, Kathleen Dotts, Christie Schaeffer, Vepkhia Pilauri, James E. Hopper · 2013 · Molecular and Cellular Biology
61. Multilayer perceptron neural networking for prediction of quality attributes of spray-dried vegetable oil powder
    Mousumi Ghosh, Shubhangi Srivastava, Rakesh Kumar Raigar, Hari Niwas Mishra · 2019 · Soft Computing
62. Combined Treatment with an Oncolytic Adenovirus and Antitumor Activity of Vincristine against Retinoblastoma Cells
    Xin Song, Haibo Wang, Renbing Jia, Biyun Cun, Xiaoping Zhao, Yixiong Zhou, Xiaofang Xu, Guanxiang Qian, Shengfang Ge, Xianqun Fan · 2012 · International Journal of Molecular Sciences
63. MDM4 binds ligands via a mechanism in which disordered regions become structured
    Maria C. Sanchez, Jonathan Renshaw, Gareth M. Davies, Paul Nigel Barlow, Martin Vogtherr · 2010 · FEBS Letters
64. p53 Pathway Alterations in Brain Tumors
    Shaoman Yin, Erwin G. Van Meir · 2009 · Humana Press eBooks
65. The Zn-finger domain of MdmX suppresses cancer progression by promoting genome stability in p53-mutant cells
    Zdenka Matijašević, Anna Krzywicka-Racka, Greenfield Sluder, Jean‐Nicolas Gallant, Stephen N. Jones · 2016 · Oncogenesis
66. Functional Activation of Mutant p53 by Platinum Analogues in Cisplatin-Resistant Cells Is Dependent on Phosphorylation
    Xiaolei Xie, Guangan He, Zahid Hussain Siddik · 2016 · Molecular Cancer Research
67. An expert overview of emerging therapies for acute myeloid leukemia: novel small molecules targeting apoptosis, p53, transcriptional regulation and metabolism
    Kapil Saxena, Marina Y Konopleva · 2020 · Expert Opinion on Investigational Drugs
68. Searching for Dual Inhibitors of the MDM 2‐p53 and MDMX ‐p53 Protein–Protein Interaction by a Scaffold‐Hopping Approach
    Andrey V. Zaytsev, Barry Dodd, Matteo Magnani, Chiara Ghiron, Bernard T. Golding, Roger J. Griffin, Junfeng Liu, Xiaohong Lü, Iolanda Micco, David R. Newell et al. · 2014 · Chemical Biology & Drug Design
69. HDMX regulates p53 activity and confers chemoresistance to 3-Bis(2-chloroethyl)-1-nitrosourea
    Genglin Jin, Stephen Cook, Bo Cui, William Chen, Stephen Thomas Keir, Patrick J. Killela, Chunhui Di, Cathy A. Payne, Simon G. Gregory, Roger E. McLendon et al. · 2010 · Neuro-Oncology
70. Role of the N-terminal lid in regulating the interaction of phosphorylated MDMX with p53
    Jane Vin Chan, Dawn X. P. Koh, Yun Liu, Thomas Leonard Joseph, David Philip Lane, Chandra Shekhar Verma, Yaw Sing Tan · 2017 · Oncotarget
71. MDM2/MDMX inhibitor peptide: WO2008106507
    Antonio Macchiarulo, Roberto Pellicciari · 2009 · Expert Opinion on Therapeutic Patents
72. TP53/miR-129/MDM2/4/TP53 feedback loop modulates cell proliferation and apoptosis in retinoblastoma
    Xiaolei Yao, Hui Shen, Qinghua Peng, Jingsheng Yu · 2021 · Cell Cycle
73. MDM4 overexpression contributes to synoviocyte proliferation in patients with rheumatoid arthritis
    Nanwei Xu, Yuji Wang, Dawei Li, Guoqiang Chen, Rongbin Sun, Ruixia Zhu, Sai Sun, Hongwei Liu, Guang Yang, Tianhua Dong · 2010 · Biochemical and Biophysical Research Communications
74. Pharmacological Rescue of p53 in Cancer Therapy: Widening the Sensitive Tumor Spectrum by Targeting MDMX
    Jean‐Christophe Marine · 2010 · Cancer Cell
75. Mutation analysis of the MDM4gene in German breast cancer patients
    Scarlett Reincke, Lina Govbakh, Bettina Wilhelm, Haiyan Jin, Natalia Viktorovna Bogdanova, Michael Bremer, Johann Hinrich Karstens, Thilo Dörk · 2008 · BMC Cancer
76. Probing Difference in Binding Modes of Inhibitors to MDMX by Molecular Dynamics Simulations and Different Free Energy Methods
    Shuhua Shi, Shaolong Zhang, Qinggang Zhang · 2015 · PLoS ONE
77. D ‐Peptide‐Based Drug Discovery Aided by Chemical Protein Synthesis
    Le Zhao, Wuyuan Lu · 2011 · Israel Journal of Chemistry
78. Bridged Analogues for p53-Dependent Cancer Therapy Obtained by S-Alkylation
    Ewa D. Micewicz, Shantanu K. Sharma, Alan J. Waring, Hai T. Luong, William H. McBride, Piotr P. Ruchala · 2015 · International Journal of Peptide Research and Therapeutics
79. -Amino acid mutation of PMI as potent dual peptide inhibitors of p53-MDM2/MDMX interactions
    Xiang Li, Chao Liu, Si Chen, Honggang Hu, Jiacan Su, Yan Zou · 2017 · Bioorganic & Medicinal Chemistry Letters
80. New insights into cancer: MDM2 binds to the citrullinating enzyme PADI4
    Salomé Araujo‐Abad, Bruno Rizzuti, Adrián Villamarin‐Ortiz, David Pantoja‐Uceda, Celia M. Moreno‐Gonzalez, Olga Abián, Adrián Velázquez‐Campoy, José L. Neira, Camino de Juan Romero · 2023 · Protein Science
81. Functional profiling of p53-binding sites in Hdm2 and Hdmx using a genetic selection system
    Shreya Datta, Megan E. Bucks, Dipankar Koley, Pei Xin Lim, Sergey N. Savinov · 2010 · Bioorganic & Medicinal Chemistry
82. A Left‐Handed Solution to Peptide Inhibition of the p53–MDM2 Interaction
    Min Liu, Marzena Pazgier, Changqing Li, Weirong Yuan, Chong Li, Wuyuan Lu · 2010 · Angewandte Chemie
83. A PRISMA-compliant meta-analysis of MDM4 genetic variants and cancer susceptibility
    Yajing Zhai, Zhijun Dai, Hairong He, Fan Gao, Lihong Yang, Yalin Dong, Jun Lü · 2016 · Oncotarget
84. Computational modeling of cyclic peptide inhibitor–MDM2/MDMX binding through global docking and Gaussian accelerated molecular dynamics simulations
    Yeng-Tseng Wang, Tian‐Lu Cheng · 2020 · Journal of Biomolecular Structure and Dynamics
85. Association of MDM4 Gene rs4245739 Polymorphism with the Risk and Clinical Characteristics of Colorectal Cancer in a Chinese Han Population
    De-Ming Zhao, Yu‐E Diao, Qing Xu · 2020 · Pharmacogenomics and Personalized Medicine
86. Jetzt wird es ernst: strukturbasiertes Design von Mdm2/Mdmx‐p53‐Inhibitoren
    Grzegorz M. Popowicz, Alexander S. S. Dömling, Tad A. Holak · 2011 · Angewandte Chemie
87. Correlation of TP53 and MDM2 Genotypes and Clinical Outcome in Platinum-Treated Head and Neck Cancer Patients with More than 10 Years’ Follow-Up
    Daniela Vivenza, Martino Monteverde, Laura Lattanzio, Federica Tonissi, Valentina Astesana, Nerina Denaro, Alberto Comino, Elvio Grazioso Russi, Cristiana Lo Nigro, Marco Carlo Merlano · 2016 · The International Journal of Biological Markers
88. BH3-mimetics or DNA-damaging agents in combination with RG7388 overcome p53 mutation-induced resistance to MDM2 inhibition
    Nikolay V. Pervushin, Dmitry K. Nilov, Sergey V. Pushkarev, Victoria O. Shipunova, Бадлаева Алина Станиславовна, Maria A. Yapryntseva, Daria V. Kopytova, Boris Zhivotovsky, Gelina S. Kopeina · 2024 · APOPTOSIS
89. Investigation on the Genomic Characterization of Uterine Sarcoma for rAd- p53 Combined with Chemotherapy Treatment
    Yu Xia, Lei Wang, Xiaolin Ma, Xiuqin Li · 2020 · Human Gene Therapy
90. Functional Interrogation of the N-Terminal Lid of MDMX in p53 Binding via Native Chemical Ligation
    Xishan Chen, Weiyue Lu · 2016 · Chemical and Pharmaceutical Bulletin
91. A Dual-Specificity d -Peptide Antagonist of MDM2 and MDMX for Antitumor Immunotherapy
    Chongbing Liao, Jin Yan, William David Tolbert, Xishan Chen, Marzena Pazgier, Weiyue Lu, Changyou Zhan, Wuyuan Lu · 2025 · Journal of Medicinal Chemistry
92. p53 regulation by ubiquitin and ubiquitin-like modifications
    Ying Wang, Chenlu Zhang, Jiabao Wang, Jiang Liu · 2022 · Genome Instability & Disease
93. Atomistic Insights Into the Regulatory Mechanisms Mediated by Post- Translational Modifications: Molecular Dynamics Investigations
    Elena Papaleo, Nicola Andrea Casiraghi, Alberto Arrigoni, Valeria Ranzani · 2012 · Current Physical Chemistry
94. Biology of Retinoblastoma
    Michael A. Dyer · 2009 · Pediatric oncology
95. p53/MDM2 Antagonists: Towards Nongenotoxic Anticancer Treatments
    Kareem Khoury, Tad A. Holak, Alexander S. S. Dömling · 2013 · Methods and principles in medicinal chemistry
96. P53 Network in Ovarian Cancer
    Fabiola Moretti, Francesca Mancini · 2012 · InTech eBooks
97. Natural compounds as a basis for the design of modulators of p53 activity
    Maxim Gureev, Pavel B. Davidovich, Vyacheslav G. Tribulovich, Alexander V. Garabadzhiu · 2014 · Russian Chemical Bulletin
98. The p53-Mdm2 Loop: A Critical Juncture of Stress Response
    Yaara Levav-Cohen, Zehavit Goldberg, Osnat Alsheich-Bartok, Valentina Zuckerman, Sue Haupt, Ygal Haupt · 2010 · Molecular biology intelligence unit
99. P53 and Cell Death
    Kamil Wolyniec, Sue Haupt, Ygal Haupt · 2009 · Wiley eBooks
100. Set the Tone:
     2018 · Yale University Press eBooks